Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Methods for high-dimensonal analysis of cells dissociated from cyropreserved synovial tissue.

Donlin LT, Rao DA, Wei K, Slowikowski K, McGeachy MJ, Turner JD, Meednu N, Mizoguchi F, Gutierrez-Arcelus M, Lieb DJ, Keegan J, Muskat K, Hillman J, Rozo C, Ricker E, Eisenhaure TM, Li S, Browne EP, Chicoine A, Sutherby D, Noma A; Accelerating Medicines Partnership RA/SLE Network, Nusbaum C, Kelly S, Pernis AB, Ivashkiv LB, Goodman SM, Robinson WH, Utz PJ, Lederer JA, Gravallese EM, Boyce BF, Hacohen N, Pitzalis C, Gregersen PK, Firestein GS, Raychaudhuri S, Moreland LW, Holers VM, Bykerk VP, Filer A, Boyle DL, Brenner MB, Anolik JH.

Arthritis Res Ther. 2018 Jul 11;20(1):139. doi: 10.1186/s13075-018-1631-y.

2.

Impaired TLR9 responses in B cells from patients with systemic lupus erythematosus.

Gies V, Schickel JN, Jung S, Joublin A, Glauzy S, Knapp AM, Soley A, Poindron V, Guffroy A, Choi JY, Gottenberg JE, Anolik JH, Martin T, Soulas-Sprauel P, Meffre E, Korganow AS.

JCI Insight. 2018 Mar 8;3(5). pii: 96795. doi: 10.1172/jci.insight.96795. [Epub ahead of print]

3.

Neutrophils Slow Disease Progression in Murine Lupus via Modulation of Autoreactive Germinal Centers.

Bird AK, Chang M, Barnard J, Goldman BI, Meednu N, Rangel-Moreno J, Anolik JH.

J Immunol. 2017 Jul 15;199(2):458-466. doi: 10.4049/jimmunol.1700354. Epub 2017 Jun 5.

4.

Inhibition of G Protein βγ Subunit Signaling Abrogates Nephritis in Lupus-Prone Mice.

Rangel-Moreno J, To JY, Owen T, Goldman BI, Smrcka AV, Anolik JH.

Arthritis Rheumatol. 2016 Sep;68(9):2244-56. doi: 10.1002/art.39673.

5.

Production of RANKL by Memory B Cells: A Link Between B Cells and Bone Erosion in Rheumatoid Arthritis.

Meednu N, Zhang H, Owen T, Sun W, Wang V, Cistrone C, Rangel-Moreno J, Xing L, Anolik JH.

Arthritis Rheumatol. 2016 Apr;68(4):805-16. doi: 10.1002/art.39489.

6.

New insights into B cell biology in systemic lupus erythematosus and Sjögren's syndrome.

Bird AK, Meednu N, Anolik JH.

Curr Opin Rheumatol. 2015 Sep;27(5):461-7. doi: 10.1097/BOR.0000000000000201. Review.

7.

Expansion of Activated Peripheral Blood Memory B Cells in Rheumatoid Arthritis, Impact of B Cell Depletion Therapy, and Biomarkers of Response.

Adlowitz DG, Barnard J, Biear JN, Cistrone C, Owen T, Wang W, Palanichamy A, Ezealah E, Campbell D, Wei C, Looney RJ, Sanz I, Anolik JH.

PLoS One. 2015 Jun 5;10(6):e0128269. doi: 10.1371/journal.pone.0128269. eCollection 2015.

8.

NOTCH inhibits osteoblast formation in inflammatory arthritis via noncanonical NF-κB.

Zhang H, Hilton MJ, Anolik JH, Welle SL, Zhao C, Yao Z, Li X, Wang Z, Boyce BF, Xing L.

J Clin Invest. 2014 Jul;124(7):3200-14. doi: 10.1172/JCI68901. Epub 2014 Jun 2.

9.

Long-term B cell depletion in murine lupus eliminates autoantibody-secreting cells and is associated with alterations in the kidney plasma cell niche.

Wang W, Rangel-Moreno J, Owen T, Barnard J, Nevarez S, Ichikawa HT, Anolik JH.

J Immunol. 2014 Apr 1;192(7):3011-20. doi: 10.4049/jimmunol.1302003. Epub 2014 Feb 26.

10.

Neutrophil-mediated IFN activation in the bone marrow alters B cell development in human and murine systemic lupus erythematosus.

Palanichamy A, Bauer JW, Yalavarthi S, Meednu N, Barnard J, Owen T, Cistrone C, Bird A, Rabinovich A, Nevarez S, Knight JS, Dedrick R, Rosenberg A, Wei C, Rangel-Moreno J, Liesveld J, Sanz I, Baechler E, Kaplan MJ, Anolik JH.

J Immunol. 2014 Feb 1;192(3):906-18. doi: 10.4049/jimmunol.1302112. Epub 2013 Dec 30.

11.

B cell biology: implications for treatment of systemic lupus erythematosus.

Anolik JH.

Lupus. 2013 Apr;22(4):342-9. doi: 10.1177/0961203312471576. Review.

PMID:
23553777
12.

Treatment targets in systemic lupus erythematosus: biology and clinical perspective.

Marian V, Anolik JH.

Arthritis Res Ther. 2012;14 Suppl 4:S3. doi: 10.1186/ar3917. Epub 2012 Nov 30. Review.

13.

Quantitative proteomics of parotid saliva in primary Sjögren's syndrome.

Ambatipudi KS, Swatkoski S, Moresco JJ, Tu PG, Coca A, Anolik JH, Gucek M, Sanz I, Yates JR 3rd, Melvin JE.

Proteomics. 2012 Oct;12(19-20):3113-20. doi: 10.1002/pmic.201200208. Epub 2012 Sep 10.

14.

Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor.

Kobie JJ, Zheng B, Bryk P, Barnes M, Ritchlin CT, Tabechian DA, Anandarajah AP, Looney RJ, Thiele RG, Anolik JH, Coca A, Wei C, Rosenberg AF, Feng C, Treanor JJ, Lee FE, Sanz I.

Arthritis Res Ther. 2011;13(6):R209. doi: 10.1186/ar3542. Epub 2011 Dec 16.

15.

Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells.

Ichikawa HT, Conley T, Muchamuel T, Jiang J, Lee S, Owen T, Barnard J, Nevarez S, Goldman BI, Kirk CJ, Looney RJ, Anolik JH.

Arthritis Rheum. 2012 Feb;64(2):493-503. doi: 10.1002/art.33333. Erratum in: Arthritis Rheum. 2012 Mar;64(3):939.

16.

B cell immunology for the clinician.

Marcus C, Dhillon G, Anolik JH.

Pediatr Infect Dis J. 2011 Feb;30(2):158-60. doi: 10.1097/INF.0b013e318207447f. Review. No abstract available.

17.

Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus.

Bekar KW, Owen T, Dunn R, Ichikawa T, Wang W, Wang R, Barnard J, Brady S, Nevarez S, Goldman BI, Kehry M, Anolik JH.

Arthritis Rheum. 2010 Aug;62(8):2443-57. doi: 10.1002/art.27515.

18.

B-cell biology and related therapies in systemic lupus erythematosus.

Ahmed S, Anolik JH.

Rheum Dis Clin North Am. 2010 Feb;36(1):109-30, viii-ix. doi: 10.1016/j.rdc.2009.12.002.

PMID:
20202594
19.

B cells in the pathogenesis and treatment of rheumatoid arthritis.

Marston B, Palanichamy A, Anolik JH.

Curr Opin Rheumatol. 2010 May;22(3):307-15. doi: 10.1097/BOR.0b013e3283369cb8. Review.

20.

Novel human transitional B cell populations revealed by B cell depletion therapy.

Palanichamy A, Barnard J, Zheng B, Owen T, Quach T, Wei C, Looney RJ, Sanz I, Anolik JH.

J Immunol. 2009 May 15;182(10):5982-93. doi: 10.4049/jimmunol.0801859.

21.

Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets.

Anolik JH, Looney RJ, Lund FE, Randall TD, Sanz I.

Immunol Res. 2009 Dec;45(2-3):144-58. doi: 10.1007/s12026-009-8096-7. Epub 2009 Apr 7. Review.

22.

Two negative randomized controlled trials in lupus: now what?

Coca A, Anolik JH.

F1000 Med Rep. 2009 May 8;1. pii: 28. doi: 10.3410/M1-28.

23.

Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndrome.

Mehta LR, Samuelsson MK, Kleiner AK, Goodman AD, Anolik JH, Looney RJ, Schwid SR.

Mult Scler. 2008 Apr;14(3):425-7. doi: 10.1177/1352458507084107. Epub 2008 Jan 21.

PMID:
18208886
24.

Targeted biologic approaches to the treatment of systemic vasculitis.

Coca A, Anolik JH.

Clin Rev Allergy Immunol. 2008 Oct;35(1-2):79-87. doi: 10.1007/s12016-007-8072-8. Review.

PMID:
18181033
25.

Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks.

Anolik JH, Ravikumar R, Barnard J, Owen T, Almudevar A, Milner EC, Miller CH, Dutcher PO, Hadley JA, Sanz I.

J Immunol. 2008 Jan 15;180(2):688-92.

26.

B cell biology and dysfunction in SLE.

Anolik JH.

Bull NYU Hosp Jt Dis. 2007;65(3):182-6. Review.

27.

Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy.

Anolik JH, Barnard J, Owen T, Zheng B, Kemshetti S, Looney RJ, Sanz I.

Arthritis Rheum. 2007 Sep;56(9):3044-56.

28.

B cell depletion therapy in autoimmune diseases.

Sanz I, Anolik JH, Looney RJ.

Front Biosci. 2007 Jan 1;12:2546-67. Review.

PMID:
17127262
29.

B-cell-targeted therapy for systemic lupus erythematosus.

Sabahi R, Anolik JH.

Drugs. 2006;66(15):1933-48.

PMID:
17100405
30.

B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny.

Anolik JH, Friedberg JW, Zheng B, Barnard J, Owen T, Cushing E, Kelly J, Milner EC, Fisher RI, Sanz I.

Clin Immunol. 2007 Feb;122(2):139-45. Epub 2006 Sep 27.

PMID:
17008130
31.

Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus.

Cappione A 3rd, Anolik JH, Pugh-Bernard A, Barnard J, Dutcher P, Silverman G, Sanz I.

J Clin Invest. 2005 Nov;115(11):3205-16. Epub 2005 Oct 6.

32.

New treatments for SLE: cell-depleting and anti-cytokine therapies.

Anolik JH, Aringer M.

Best Pract Res Clin Rheumatol. 2005 Oct;19(5):859-78. Review.

PMID:
16150407
33.

Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus.

Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, Sanz I.

Arthritis Rheum. 2004 Nov;50(11):3580-90.

34.

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.

Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I.

Arthritis Rheum. 2004 Aug;50(8):2580-9.

35.

Lupus IgG VH4.34 antibodies bind to a 220-kDa glycoform of CD45/B220 on the surface of human B lymphocytes.

Cappione AJ, Pugh-Bernard AE, Anolik JH, Sanz I.

J Immunol. 2004 Apr 1;172(7):4298-307.

36.

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, Looney RJ.

Arthritis Rheum. 2003 Feb;48(2):455-9.

37.

Posttransfusion purpura secondary to an alloantibody reactive with HPA-5a (Br(b)).

Anolik JH, Blumberg N, Snider J, Francis CW.

Transfusion. 2001 May;41(5):633-6.

PMID:
11346699
38.

Multifocal Staphylococcus aureus infection originating from the sacroiliac joint in a patient with rheumatoid arthritis.

Anolik JH, Wildy K, Cohn SE, Marquardt JD, Totterman S, Zwillich SH.

J Rheumatol. 2001 Jan;28(1):217-20. No abstract available.

PMID:
11196533
39.

Effect of isotretinoin therapy on natural killer cell activity in patients with xeroderma pigmentosum.

Anolik JH, Di Giovanna JJ, Gaspari AA.

Br J Dermatol. 1998 Feb;138(2):236-41.

PMID:
9602867
40.

Effects of multiple estrogen responsive elements, their spacing, and location on estrogen response of reporter genes.

Sathya G, Li W, Klinge CM, Anolik JH, Hilf R, Bambara RA.

Mol Endocrinol. 1997 Dec;11(13):1994-2003.

PMID:
9415403
41.

Stability of the ligand-estrogen receptor interaction depends on estrogen response element flanking sequences and cellular factors.

Anolik JH, Klinge CM, Brolly CL, Bambara RA, Hilf R.

J Steroid Biochem Mol Biol. 1996 Dec;59(5-6):413-29.

PMID:
9010347
42.

Cooperative binding of estrogen receptor to DNA depends on spacing of binding sites, flanking sequence, and ligand.

Anolik JH, Klinge CM, Hilf R, Bambara RA.

Biochemistry. 1995 Feb 28;34(8):2511-20.

PMID:
7873531
43.

Supplemental Content

Loading ...
Support Center